tirzepatide alcohol use disorder Shows Promise for tirzepatide and alcohol interaction Could

Tirzepatide shows slightly greater average weight loss in clinical trials (15-22% vs 15% body weight), but individual response varies

"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial." Lancet , 398(10295), 143-155

doi: 10.1038/s41574-020-00435-4

Mounjaro kombiniert diesen Effekt mit der GIP-Wirkung

This usage could drive a broader and more lasting behavioral shift among this large demographicone that represents a disproportionate share of food consumption

Many patients experience minimal weight loss during this period, which is completely normal and expected